Eli Lil­ly in­vests $450M to ex­pand its North Car­oli­na Re­search Tri­an­gle man­u­fac­tur­ing site

Af­ter a busy year of man­u­fac­tur­ing build­outs in 2022, Eli Lil­ly is al­ready back at it with a $450 mil­lion in­vest­ment. Lil­ly is plan­ning to ex­pand its fa­cil­i­ty in the Re­search Tri­an­gle in North Car­oli­na, adding 100 new jobs at the fa­cil­i­ty, main­ly man­u­fac­tur­ing per­son­nel.

The ex­pan­sion, an­nounced on Tues­day, is slat­ed to be com­plet­ed in 2027 and will add ad­di­tion­al ca­pac­i­ty for “par­enter­al fill­ing” as well as more space for the as­sem­bly of de­vices and pack­ag­ing ca­pac­i­ty. Con­struc­tion will be­gin this year, but no ex­act date has been set.

The ex­pan­sion will al­so sup­port and in­crease de­mand for its in­cretin prod­ucts that help treat di­a­betes, Lil­ly said in a press re­lease. How­ev­er, there are no de­tails on the size of the ex­pan­sion. End­points News reached out for fur­ther com­ment but did not re­ceive a re­sponse by press time.

Edgar­do Her­nan­dez

“Ex­pand­ing our op­er­a­tions at Re­search Tri­an­gle Park will ac­cel­er­ate the rate at which we can pro­duce med­i­cines that pa­tients re­ly on to ad­dress se­ri­ous health chal­lenges like di­a­betes. We’re on track to achieve the goal we shared in No­vem­ber 2022 of dou­bling in­cretin ca­pac­i­ty by the end of this year, but this in­vest­ment is key to en­sur­ing even more pa­tients will have ac­cess to med­i­cines they need in the fu­ture,” Edgar­do Her­nan­dez, SVP and pres­i­dent of Lil­ly’s man­u­fac­tur­ing op­er­a­tions, said in a state­ment.

Lil­ly’s site in Re­search Tri­an­gle Park has seen a lot of in­vest­ment in the past few years, in­clud­ing a $1.7 bil­lion ex­pan­sion in 2020. Ac­cord­ing to NCbiotech.org, the site was ini­tial­ly meant to house more than 460 work­ers. Lil­ly has made North Car­oli­na a ma­jor fo­cus, with the In­di­anapo­lis phar­ma plan­ning to in­vest $1 bil­lion in­to its Con­cord, NC fa­cil­i­ty. It will fo­cus on the man­u­fac­tur­ing of in­jecta­bles and med­ical de­vices.

Lil­ly’s em­pha­sis on boost­ing man­u­fac­tur­ing ca­pac­i­ty is no se­cret. A re­port from SVB Se­cu­ri­ties from last No­vem­ber said that Lil­ly is ex­pect­ed to dou­ble the man­u­fac­tur­ing ca­pac­i­ty for the di­a­betes drug Moun­jaro by the end of 2023, with some pro­duc­tion for Moun­jaro com­ing on­line be­fore then. But Lil­ly did not dis­close to SVB how Moun­jaro’s de­mand com­pares with ex­ist­ing man­u­fac­tur­ing ca­pac­i­ty.

The Re­search Tri­an­gle it­self is al­so a hotbed of man­u­fac­tur­ing ac­tiv­i­ty as well, with com­pa­nies such as Catal­ent, Fu­ji­film, and Astel­las start­ing or cap­ping off mul­ti­mil­lion-dol­lar projects in the area.

Raymond Stevens, Structure Therapeutics CEO

Be­hind Fri­day's $161M IPO: A star sci­en­tist, GPCR drug dis­cov­ery and a plan to chal­lenge phar­ma in di­a­betes

What does it take to pull off a $161 million biotech IPO these days?

In Structure Therapeutics’ case, it means having a star scientist co-founder paired with the computational drug discovery company Schrödinger, $198 million in private funding from blue-chip investors, almost six years of research work on G protein-coupled receptors and a slate of oral, small-molecule drugs, with an eye on the huge and growing diabetes and weight-loss market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Sen. Ron Wyden (D-OR) (Francis Chung/E&E News/Politico via AP Images)

In­fla­tion re­bates in­com­ing: Wyden calls on CMS to move quick­ly as No­var­tis CEO pledges re­ver­sal

Senate Finance Chair Ron Wyden (D-OR) this week sent a letter to the head of the Centers for Medicare & Medicaid Services seeking an update on how and when new inflation-linked rebates will take effect for drugs that see major price spikes.

The newly signed Inflation Reduction Act requires manufacturers to pay a rebate to Medicare when they increase drug prices faster than the rate of inflation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Uğur Şahin, BioNTech CEO (Andreas Arnold/picture-alliance/dpa/AP Images)

BioN­Tech opens new plas­mid DNA man­u­fac­tur­ing fa­cil­i­ty in Ger­many

German mRNA player BioNTech opened the doors to a new manufacturing facility on Thursday, this one just about 75 miles north of its headquarters in Mainz, Germany.

BioNTech announced on Thursday that it has completed the construction of its first plasmid DNA manufacturing facility in Marburg, Germany. The facility will produce materials for mRNA-based vaccines and therapies along with cell therapies.

Teresa Graham, incoming Roche Pharmaceuticals CEO

In­com­ing Roche CEO builds out his top team, tap­ping Genen­tech vet to lead phar­ma di­vi­sion

Roche announced another leadership shuffle Thursday morning – the head of global product strategy, Teresa Graham, will take over as CEO of Roche Pharmaceuticals in March while the company’s corporate executive committee will make a spot for Levi Garraway, CMO and executive VP of global product development.

Thomas Schinecker will take over the top spot as Roche group CEO in March, leaving his spot as head of diagnostics.

Trodelvy notch­es a win in most com­mon form of breast can­cer

Following a promise last year to go “big and fast in breast cancer,” Gilead has secured a win for Trodelvy in the most common form.

The drug was approved to treat HR-positive, HER2-negative breast cancer patients who’ve already received endocrine-based therapy and at least two other systemic therapies for metastatic cancer, Gilead announced on Friday.

Trodelvy won its first indication in metastatic triple-negative breast cancer back in 2020, and has since added urothelial cancer to the list. HR-positive HER2-negative breast cancer accounts for roughly 70% of new breast cancer cases worldwide per year, according to senior VP of oncology clinical development Bill Grossman, and many patients develop resistance to endocrine-based therapies or worsen on chemotherapy.

Af­ter 13 years, Ramy Mah­moud steps in­to CEO seat at Opti­nose; Ru­pert Vessey set to ex­it Bris­tol My­ers in Ju­ly

After 13 years as president and COO at Optinose, Ramy Mahmoud has stepped into a new role as its CEO. He is taking the place of Peter Miller, who stepped down earlier this week, though Miller is still staying with the company as a consultant.

In 2010, the two business partners joined Optinose to take it in a new direction, transforming it from a delivery platform to product company. They previously worked together at Johnson & Johnson, when Miller was president at Janssen and Mahmoud headed medical affairs. Miller said after he learned about Optinose, “I did what I always do, which is find people smarter than me to talk with about the idea. And the first person I called was Ramy … and I said, ‘Hey, Ramy, what do you think of this technology?’”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Te­va drops out of in­dus­try trade group PhRMA

Following in AbbVie’s footsteps, Teva confirmed on Friday that it’s dropping out of the industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA).

Teva didn’t give a reason for its decision to leave, saying only in a statement to Endpoints News that it annually reviews “effectiveness and value of engagements, consultants and memberships to ensure our investments are properly seated.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)

Sanofi sees downtick in flu sales as it preps for launch of RSV an­ti­body

Sanofi expects its RSV antibody jointly developed with AstraZeneca will be available next season, executive VP of vaccines Thomas Triomphe announced on the company’s quarterly call.

Beyfortus, also known as nirsevimab, was approved in the EU back in November and is currently under FDA review with an expected decision coming in the third quarter of this year. The news comes as the FDA plans to hold advisory committee meetings over the next couple months to review RSV vaccines from Pfizer and GSK.

Christophe Weber, Takeda CEO (Photographer: Shoko Takayasu/Bloomberg via Getty Images)

Take­da fo­cus­es on ‘di­verse’ pipeline prospects on heels of two ac­qui­si­tions

After a whopping $4 billion asset buy from Nimbus Therapeutics, along with a $400 million deal with Hutchmed for a colorectal cancer drug, Takeda executives touted pipeline optimism on its latest earnings call this week.

That’s because the TYK2 inhibitor for psoriasis Takeda is getting from Nimbus, along with the Hutchmed fruquintinib commercialization outside of China, are just two of what it reports are 10 late-stage development programs of promising candidates.